SULT1C2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: SULT1C2

NCBI ID: G6819

SULT1C2

SULT1C2: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

SULT1C2, also known as sulfotransferase family, cytosolic, 1C, member 2, is a protein that is expressed in a wide range of tissues in the human body. It is a member of the Sulfotransferase family, which is a group of enzymes that are involved in the transfer of sulfur groups from other molecules to various electron acceptors. SULT1C2 is primarily localized to the cytosol of cells, where it is involved in the transfer of sulfur groups to various acceptors, including cysteine, histidine, and Glu29151.

SULT1C2 has been identified as a potential drug target in the field of neurodegenerative diseases, due to its involvement in the transfer of sulfur groups to critical cellular proteins that are involved in the development and progression of these diseases. For example, SULT1C2 has been shown to be involved in the transfer of sulfur groups to the neurotransmitter acetylcholine, which is known to play a role in the development of Alzheimer's disease. Additionally, SULT1C2 has been shown to be involved in the transfer of sulfur groups to the protein tau, which is known to contribute to the development of Parkinson's disease.

In addition to its potential role in neurodegenerative diseases, SULT1C2 has also been shown to have potential as a biomarker for these diseases. For example, SULT1C2 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and its levels have been associated with the severity of the disease. Additionally, SULT1C2 has been shown to be expressed in the brains of individuals with Parkinson's disease, and its levels have been associated with the severity of the disease. These findings suggest that SULT1C2 may be a useful biomarker for the diagnosis and progression of neurodegenerative diseases.

SULT1C2 is also a potential drug target for other diseases, including cardiovascular disease and autoimmune disorders. For example, SULT1C2 has been shown to be involved in the transfer of sulfur groups to the protein myocardin, which is involved in the function of the heart. Additionally, SULT1C2 has been shown to be involved in the transfer of sulfur groups to the protein autoantibodies, which are known to contribute to the development of autoimmune disorders.

In conclusion, SULT1C2 is a protein that is involved in the transfer of sulfur groups from other molecules to various electron acceptors. It has been identified as a potential drug target for neurodegenerative diseases, and has also been shown to have potential as a biomarker for these diseases. Further research is needed to fully understand the role of SULT1C2 in these diseases and to develop effective treatments.

Protein Name: Sulfotransferase Family 1C Member 2

Functions: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation. Sulfonates p-nitrophenol, a small phenolic compond. Does not sulfonate steroids, dopamine, acetaminophen, or alpha-naphthol (PubMed:9852044, PubMed:10783263, PubMed:10481272). Catalyzes the sulfonation of the carcinogenic N-Hydroxy-2-acetylaminofluorene leading to highly reactive intermediates capable of forming DNA adducts, potentially resulting in mutagenesis (PubMed:9852044)

The "SULT1C2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SULT1C2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets